31 results about "Transgenic Rats" patented technology

The present invention relates to methods for producing transgenic animals, particularly transgenic rats, using retroviral constructs engineered to carry the transgene(s) of interest.

A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.

The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.

The application provides a fully human monoclonal antibody directed against member 4 of tumor necrosis factor receptor superfamily (TNFRSF4) (also known as OX40 and CD134). The application also provides a method for producing hybridomas using humanized transgenic rats, a nucleic acid molecule encoding the anti-OX40 antibody, an expression vector and a host cell for expressing the anti-OX40 antibody. The invention also provides a method for verifying antibody function in vitro and antibody efficacy in vivo. The antibody of the invention provides a very effective agent for treating a variety ofcancers by modulating human immune function.

A transgenic rat expresses a gene of interest, such as EGFP, exclusively in the germ cells of both males and females. From such a transgenic rat one can isolate a line of spermatogonial stem cells, which can renew and proliferate in culture.

This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.

The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine. In one embodiment, the invention provides a genetically modified or chimeric rat cell whose genome comprises two chromosomal alleles of a drug metabolism gene wherein at least one of the two alleles contains a mutation, or the progeny of the cell.

To provide an immortalized capillary pericyte line which maintains the original function / property of the cell line-deriving tissue, its establishment method, and the screening method for useful substance using the immortalized capillary pericyte line. Cerebral tissue of a transgenic rat carrying the large T antigen gene of SV40 thermo-sensitive mutant line tsA58 is homogenized and the resultant brain capillaries are treated with protease, thus obtained brain capillary cells are subcultured to establish an immortalized cell that expresses SV40 thermo-sensitive large T antigen, PDGF receptor β, and Angiopoietin-1. In addition, the immortalized vascular pericyte line has ability to deposit calcium on matrix by dense culture.

The patent of the present invention discloses a high-efficiency cleaning device for drinking water bottles of transgenic mice, and specifically relates to the technical field of cleaning devices. Including the cleaning box, the cleaning box is connected with a placement box, the placement box is distributed with grooves, and the neck plate is also engaged in the placement box; the cleaning box is equipped with a motor, the motor is provided with a rotating handle, and the rotating handle is provided with a cylinder. There is a cleaning board on the top, and a cleaning rod is pierced on the cleaning board. There are bristles attached to the cleaning rod. The top of the cleaning rod is located above the cleaning board. There are multiple air holes on the side wall of the cleaning rod. The bottom of the cleaning rod is connected to the rotating rod passing through the cleaning plate. Each cleaning rod is equipped with an internal gear, and the rotating rod is sequentially provided with the first gear and negative pressure. For the vane, the second gear meshes between the first gear and the internal gear, and the negative pressure vane is located in the cleaning rod. The technical scheme of the invention solves the problem of low cleaning efficiency of existing drinking water bottles, and can be used for cleaning drinking water bottles in large quantities.

The invention provides a method for constructing a transgenic rat specifically expressing hMRGPRX4 and its application. The present invention successfully constructs a humanized rat by expressing hMRGPRX4 in rat itch neurons. The transgenic rat strains were mated to obtain transgenic rats specifically expressing hMRGPRX4. The invention provides an animal model for studying the function of hMRGPRX4 and screening antipruritic drugs targeting hMRGPRX4.